SCHEMBL5135091

SCHEMBL5135091

COc1cc(-c2cc(=O)c3c(OC)cc(O)cc3o2)cc(OC)c1O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.82
AKR1B1 P15121 1/20 0.82
MAPK8 P45983 1/20 0.82
POLH Q9Y253 1/20 0.70
MAPT P10636 6/20 0.70
KDM4E B2RXH2 5/20 0.70
POLB P06746 4/20 0.70
RECQL P46063 2/20 0.70
CYP1B1 Q16678 5/20 0.63
CYP1A1 P04798 4/20 0.63
CYP1A2 P05177 4/20 0.63
MEN1 O00255 4/20 0.63
ALDH1A1 P00352 4/20 0.63
KMT2A Q03164 4/20 0.63
ABCC1 P33527 2/20 0.63
ABCB1 P08183 3/20 0.61
LCK P06239 1/20 0.60
IP6K2 Q9UHH9 2/20 0.60
KDM1A O60341 1/20 0.60
XDH P47989 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tricin SCHEMBL44475 0.90 MAOA (1.00) MAOAAKR1B1MAPK8POLHMAPT
Tricin SCHEMBL29712335 0.90 MAOA (1.00) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL16894650 0.90 ABCB1 (0.76) MAOAAKR1B1MAPK8POLHMAPT
Tricin SCHEMBL10809395 0.89 MAOA (0.97) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL7752988 0.89 MAOA (0.70) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL1676018 0.89 ABCB1 (0.78) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL12378833 0.86 MAOA (0.92) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL29576775 0.86 MAOA (0.92) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL2485835 0.86 CYP1B1 (0.83) MAOAAKR1B1MAPK8POLHMAPT
SCHEMBL2874033 0.86 POLH (0.79) MAOAAKR1B1MAPK8POLHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530426-B2 Topical use of a UGT inducer-containing composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin/hair and prevent and/or treat imperfections of the skin; flavanoids such as chrysin stimulates isoforms; protective coatings aging/ wrinkling resistance SEDERMA SAS (FR) 2013-09-10 US claimed
US-10953237-B2 Methods of providing skin care using phototherapy INDERM (FR) 2021-03-23 US disclosed
EP-3271012-B1 DEVICES FOR PROVIDING SKIN CARE USING PHOTOTHERAPY INDERM (FR) 2019-06-19 EP disclosed
US-20180071547-A1 Methods of Providing Skin Care Using Phototherapy INDERM (FR) 2018-03-15 US disclosed
EP-3271012-A1 METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY Inderm (FR) 2018-01-24 EP disclosed
EP-1776161-B1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER SEDERMA S A S (FR) 2016-10-26 EP disclosed
WO-2016146778-A1 METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY INDERM (FR) 2016-09-22 WO disclosed
US-8530426-B2 Topical use of a UGT inducer-containing composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin/hair and prevent and/or treat imperfections of the skin; flavanoids such as chrysin stimulates isoforms; protective coatings aging/ wrinkling resistance SEDERMA SAS (FR) 2013-09-10 US disclosed
US-20080213198-A1 Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer SEDERMA SAS (FR) 2008-09-04 US disclosed
EP-1776161-A1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER Sederma S.A.S. (FR) 2007-04-25 EP disclosed
WO-2005102266-A1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER SEDERMA, SAS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213198-A1 Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer UGT1A1, UGT1A3, UGDH MAOA 83/4885AKR1B1 246/4885MAPK8 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.